Cholesterol medications explained: statins, ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran

Every class of LDL-lowering drug in one place: how each one works, how far it moves LDL, how it is taken, which have trials showing fewer heart attacks and strokes, and the blood tests that show whether yours is working.

Reviewed by LifeFrom’s medical AIPublished November 20, 2026 · 11 min read
Ask AI about this pageChatGPTClaudePerplexity
The distinctions
  1. 01
    A lower LDL predicts protection; only an outcome trial counts it

    Across 49 trials, each 1 mmol/L (39 mg/dL) of LDL removed through liver LDL receptors cut major vascular events by about a quarter, whichever drug removed it 2, so the 2026 guideline sets an LDL goal and leaves the route open 1. That is still a prediction for any new drug: statins, ezetimibe, bempedoic acid, evolocumab and alirocumab have trials that counted fewer heart attacks and strokes, while inclisiran, enlicitide and lerodalcibep had LDL results only as of November 2026.

Almost every cholesterol drug ends up doing the same job: it leaves more LDL receptors on the surface of the liver, and those receptors pull LDL particles out of the blood. The drugs differ in where they push on that system, how far they move LDL, whether you swallow them or inject them, what they cost, and whether a trial has counted fewer heart attacks and strokes or, so far, only a lower LDL.

Cholesterol medications at a glance

The table lists every type of cholesterol medication, statin and non-statin, in the order a prescriber usually reaches for it. The LDL column is the drop against placebo in each drug's main trial, a guide to size rather than a ranking. The outcomes column asks whether a randomized trial has counted fewer heart attacks, strokes or cardiovascular deaths.

Drug (brand)How it is takenLDL drop in trialsFewer heart attacks and strokes shown?Main watch-outLab to watch
Statins: atorvastatin (Lipitor), rosuvastatin (Crestor) and othersDaily pill30 to 49% (moderate), 50% or more (high intensity) 1Yes, the deepest evidenceMuscle aches, small rise in blood sugarLipid panel; creatine kinase (CK, a muscle-damage test) only if muscles hurt
Ezetimibe (Zetia)Daily pill, genericAbout 18% alone, per its label; about 23% more on a statin in IMPROVE-IT 3Yes, IMPROVE-IT 3Few; liver enzymes can rise with a statinALT, a liver enzyme
Bempedoic acid (Nexletol; Nexlizet with ezetimibe)Daily pillAbout 21% 4; about 38% with ezetimibeYes, in people who could not take a statin 4Gout, gallstones, tendon ruptureUric acid
Evolocumab (Repatha), alirocumab (Praluent)Injection every 2 weeks, or monthly (evolocumab) or every 4 weeks (alirocumab)About 59% 5Yes: FOURIER, ODYSSEY OUTCOMES, VESALIUS-CV 5 6 7Injection-site reactionsLipid panel
Lerodalcibep (Lerochol)Monthly injection, can be stored at room temperatureAbout 56% 14Not yetInjection-site reactions, about 7% 14Lipid panel
Enlicitide (Lipfendra)Daily pill on an empty stomachAbout 56 to 59% 9Not yet 9Little long-term data so farLipid panel
Inclisiran (Leqvio)Clinic injection at the start, at 3 months, then every 6 monthsAbout 50% 8Not yet; ORION-4 not reportedInjection-site reactionsLipid panel
Bile-acid sequestrants: cholestyramine, colestipol, colesevelamPowder or tablets with mealsAbout 10 to 25%Cholestyramine, in a 1980s trial 15Bloating, constipation, higher triglycerides, binds other drugsTriglycerides

Why every route to a lower LDL counts

How a cholesterol drug becomes fewer heart attacks

1
The liver runs short of cholesterol
Statins and bempedoic acid block cholesterol production inside the liver; ezetimibe blocks absorption from the gut, so less reaches the liver.
2
The liver builds more LDL receptors
To refill its stores, the liver puts more LDL receptors, docking sites that pull LDL particles in and break them down, on its surface.
3
PCSK9 drugs stop the receptors being destroyed
PCSK9 is a protein that tags LDL receptors for destruction. Blocking PCSK9, or silencing its production as inclisiran does, lets each receptor recycle and clear more LDL.
4
Less LDL, less plaque, fewer events
Across trials of receptor-raising drugs, each 1 mmol/L (39 mg/dL) of LDL removed cut major vascular events (heart attacks, strokes, artery-opening procedures and cardiovascular deaths) by about a quarter, whichever drug removed it 2.
Mechanisms as described in each drug's trial reports; the event figure is from a 2016 JAMA meta-analysis of 49 trials by Silverman and colleagues: relative risk 0.77 per mmol/L on statins and 0.75 on non-statins that work through LDL receptors 2.

The use of statin and nonstatin therapies that act via upregulation of LDL receptor expression to reduce LDL-C were associated with similar RRs of major vascular events per change in LDL-C.Silverman MG et al., JAMA 2016 2

That result is why the guideline sets an LDL goal and lets the prescriber pick the route. For a new drug it is still a prediction, so the outcomes column says yes only when the drug's own trial has counted fewer events.

How much does your LDL need to fall?

To lower LDL cholesterol with medicine, start from the goal. The 2026 ACC/AHA dyslipidemia guideline, published in March 2026, sets LDL goals by overall heart risk and asks for a non-statin whenever the goal is not reached on the most statin a person can take, in whatever order suits patient and clinician 1.

Risk group (2026 ACC/AHA) 1LDL goal, mg/dLLDL goal, mmol/L
Borderline to intermediate riskUnder 100Under 2.6
High risk, or heart disease not at very high riskUnder 70Under 1.8
Very high-risk heart diseaseUnder 55Under 1.4

Not sure which group you are in? Ask the clinician which goal they are using for you. It depends on age, blood pressure, diabetes, smoking and any past heart attack or stroke, and a coronary calcium score can move someone up or down a group; high cholesterol covers how the groups are set.

The size of the drop a goal implies is the starting LDL minus the goal, divided by the starting LDL. The examples show roughly how many layers of treatment a prescriber may weigh; the right goal and drug for you depend on your full risk picture, other medicines and history.

Example starting LDLGoalDrop neededOptions a prescriber may consider
130 mg/dL (3.4 mmol/L)Under 100 (2.6)23%A moderate-intensity statin
160 mg/dL (4.1 mmol/L)Under 70 (1.8)56%A high-intensity statin, usually plus ezetimibe
190 mg/dL (4.9 mmol/L)Under 55 (1.4)71%A high-intensity statin plus a PCSK9 drug, often with ezetimibe too (statin plus ezetimibe alone reaches about 61%)

An LDL of 190 mg/dL or more before any treatment raises the question of familial hypercholesterolemia, an inherited receptor problem that changes the starting plan. An LDL of 70 mg/dL has its own page, and food adds to any medicine: foods that lower cholesterol and the DASH diet cover that half of lowering LDL.

CalculatorCholesterol converterReads your LDL in mg/dL or mmol/L so you can set it against the goals aboveWork it out

Statins come first, and why

Statins block HMG-CoA reductase, the liver enzyme that makes cholesterol. A moderate-intensity dose lowers LDL by 30 to 49 percent and a high-intensity dose by 50 percent or more 1, generic statins cost a few dollars a month, and statins have the longest run of outcome trials of any cholesterol drug. Atorvastatin and rosuvastatin are the two high-intensity options.

The dose sets the percentage; your starting LDL and heart risk decide how much protection it buys, so the same tablet can be worth several times more to one person than another.

LifeFrom, Atorvastatin

A higher statin dose is not the only lever. In RACING, 3,780 people with heart disease took rosuvastatin 10 mg plus ezetimibe or rosuvastatin 20 mg alone; over 3 years events were no more common on the combination (9.1 against 9.9 percent), more people reached an LDL under 70 mg/dL (72 against 58 percent) and fewer stopped for side effects (4.8 against 8.2 percent) 13. Nor does a stronger statin automatically buy more protection.

In the LODESTAR trial that extra strength gave no fewer deaths, heart attacks, strokes or artery procedures than atorvastatin over 3 years, and slightly more new diabetes.

LifeFrom, Rosuvastatin

Doses, interactions and side effects for the class live on the statins page; the rest of this guide covers what comes after a statin, or instead of one.

Ezetimibe (Zetia): the cheap add-on pill

Ezetimibe blocks NPC1L1, the protein that lets the gut absorb cholesterol from food and bile. With less cholesterol arriving, the liver raises its LDL receptors. It is a once-daily generic tablet costing a few dollars a month, often combined with a statin in one pill. On its own it lowers LDL by about 18 percent, according to its label; added to a statin, by roughly 20 to 25 percent more, and the drop shows within about 2 weeks.

IMPROVE-IT, the trial behind ezetimibe, gave 18,144 people who had been in hospital with an acute coronary syndrome (a heart attack or unstable angina) simvastatin with ezetimibe or with placebo. Over about 7 years, median LDL was 53.7 mg/dL (1.4 mmol/L) against 69.5 mg/dL (1.8 mmol/L), and heart attacks, strokes, cardiovascular deaths and related events fell from 34.7 percent to 32.7 percent 3. That is about 2 people in 100 spared an event over 7 years, roughly what the extra 16 mg/dL of LDL lowering predicted.

When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes.Cannon CP et al., IMPROVE-IT, N Engl J Med 2015 3

Side effects in trials sit close to placebo. Taken with a statin, ezetimibe can raise liver enzymes, so an ALT result is the number to read; liver enzymes explained covers what a rise means. Mention cyclosporine and gemfibrozil to the prescriber, because both interact with ezetimibe.

Bempedoic acid (Nexletol, Nexlizet): for people who can't take a statin

Bempedoic acid blocks ATP citrate lyase, an enzyme one step earlier in the same cholesterol-making pathway that statins block. It is switched on by an enzyme found in the liver but not in muscle, the proposed reason muscle aches are less common than on a statin. Nexlizet combines it with ezetimibe in one daily tablet, which lowers LDL by about 38 percent.

CLEAR Outcomes tested it in 13,970 people who said they could not take a statin. LDL fell 21 percent more than on placebo at 6 months, and over a median 40.6 months heart attacks, strokes, coronary procedures and cardiovascular deaths fell from 13.3 percent to 11.7 percent 4. The trade-off was more gout and gallstones.

Side effect in CLEAR OutcomesBempedoic acidPlacebo
Gout3.1%2.1% 4
Gallstones2.2%1.2% 4

Bempedoic acid raises uric acid, and the label also warns of tendon rupture. It also raises blood levels of simvastatin and pravastatin, so the label says to avoid simvastatin above 20 mg and pravastatin above 40 mg alongside it. It is brand-only and costs several hundred dollars a month without insurance.

PCSK9 inhibitors: Repatha, Praluent, Lerochol and the new pill

PCSK9 is a protein the liver releases that marks LDL receptors for destruction. Block PCSK9 and each receptor goes back to the cell surface to clear more LDL, which is why PCSK9 drugs give the largest drops of any add-on. Four products block the PCSK9 protein directly and differ mainly in how they are taken and how much proof sits behind them; inclisiran, covered next, stops the liver making PCSK9 at all.

ProductHow it is takenLDL dropOutcome trial
Evolocumab (Repatha)Injection every 2 weeks or monthly59% in FOURIER 5FOURIER, VESALIUS-CV: fewer events 5 7
Alirocumab (Praluent)Injection every 2 or 4 weeksSimilar to evolocumabODYSSEY OUTCOMES: fewer events 6
Lerodalcibep (Lerochol), approved December 2025Monthly injection, can be stored at room temperatureAbout 56% at 1 year in LIBerate-HR 14Not yet reported
Enlicitide (Lipfendra), approved July 2026Daily pill on an empty stomachAbout 56 to 59% 9Pending 9

In FOURIER, 27,564 people with heart disease already on statins took evolocumab or placebo; median LDL fell from 92 to 30 mg/dL (2.4 to 0.78 mmol/L), and the main group of events fell from 11.3 percent to 9.8 percent over a median 2.2 years 5. ODYSSEY OUTCOMES gave alirocumab to 18,924 people after an acute coronary syndrome, and major events fell from 11.1 percent to 9.5 percent over 2.8 years 6.

8.0% to 6.2%Coronary death, heart attack or ischemic stroke at 5 years, placebo against evolocumab, in people who had never had a heart attack or strokeVESALIUS-CV, 12,257 people with atherosclerosis or high-risk diabetes, 2025 7

The earlier PCSK9 trials enrolled people who had already had a heart attack, stroke or acute coronary syndrome; VESALIUS-CV is the first to show a PCSK9 drug reducing first heart attacks and strokes 7. PCSK9 antibodies also lower lipoprotein(a), an inherited cholesterol particle statins leave alone, by a median 26.9 percent in FOURIER 11; lowering Lp(a) is not an approved use, and these drugs are prescribed for LDL and heart risk. The usual side effect is redness or soreness where the injection goes in, reported by about 7 percent of people on lerodalcibep against 0.3 percent on placebo 14.

Insurers typically ask for prior authorization, a form from your prescriber showing a statin, and often ezetimibe, came first. Without insurance, evolocumab sells for about $240 a month through its maker's direct cash-price program, and the other PCSK9 drugs vary; generic ezetimibe costs a few dollars.

Inclisiran (Leqvio): a shot twice a year

Inclisiran is a small interfering RNA, a short strand that switches off the liver's instructions for making PCSK9. A clinician gives it under the skin at the start, at 3 months and then every 6 months, and it is usually billed under medical rather than pharmacy coverage. In ORION-10 and ORION-11 it lowered LDL by 52.3 percent and 49.9 percent against placebo at day 510; injection-site reactions occurred in up to about 5 percent, against under 1 percent on placebo 8.

Inclisiran's outcome trial, ORION-4, had not reported results as of November 2026, so its protection against heart attacks and strokes rests on the LDL-for-LDL prediction rather than a counted result. Prescribers may consider it for people who struggle with daily pills or injections every 2 weeks and prefer two clinic visits a year.

Stacking them: how low can LDL go?

Drug effects multiply on what is left: an add-on that lowers LDL by 23 percent removes 23 percent of what the statin left behind, not of the starting value. The chart follows one starting LDL through three layers.

LDL left after each added medicine, starting from 160 mg/dL
LDL (mg/dL)Very high-risk goal, 55 mg/dL (1.4 mmol/L)StartHigh-intensity statinPlus ezetimibePlus PCSK9 drug
Illustrative arithmetic, not a forecast for any one person: a 50 percent drop for a high-intensity statin 1, 23 percent for ezetimibe as in IMPROVE-IT 3 and 59 percent for evolocumab as in FOURIER 5, applied in turn. In mmol/L the steps are 4.1, 2.1, 1.6 and 0.65.

Very low LDL has shown no new harm in the trials so far. Among FOURIER patients whose LDL fell under 20 mg/dL (0.5 mmol/L), serious adverse events, muscle problems, new diabetes and memory or thinking problems were no more common over a median 2.2 years, and that lowest group had the fewest cardiovascular events 10.

At low LDL, the Friedewald formula many labs use to calculate LDL underestimates it; the Martin-Hopkins method, which adjusts the formula for each person's triglycerides, holds up better. If your report does not name its method and your LDL is low, enter the panel in the calculator below or ask for a direct LDL or an apoB.

CalculatorLDL calculatorRecalculates LDL from your panel with the Martin-Hopkins method, which stays accurate when LDL is low or triglycerides are highWork it out

Older and specialist drugs

Bile-acid sequestrants (cholestyramine, colestipol and colesevelam) bind bile in the gut so the liver uses cholesterol to make more. They lower LDL by about 10 to 25 percent, cause bloating and constipation, can raise triglycerides, and bind other medicines, so other drugs are spaced hours apart. Cholestyramine cut coronary events in the Lipid Research Clinics trial of 1984 15.

The other lipid drugs do different jobs; cholesterol vs triglycerides explains why the two need different drugs.

DrugWhat it treatsNote
Fibrates (fenofibrate, gemfibrozil)High triglyceridesNot an LDL drug; gemfibrozil interacts with statins
Icosapent ethyl, a prescription omega-3High triglycerides on a statinNot an LDL drug
NiacinLowers LDL and triglycerides, raises HDLNo added benefit on a statin in outcome trials
EvinacumabHomozygous familial hypercholesterolemia, the rare form where LDL receptors barely workMonthly infusion, given by specialists
LomitapideHomozygous familial hypercholesterolemiaDaily pill that needs regular liver monitoring

In two large trials of people already on a statin, AIM-HIGH and HPS2-THRIVE, those lab changes did not prevent heart attacks or strokes, and HPS2-THRIVE found more diabetes, infections and bleeding.

LifeFrom, Niacin

If you can't take a statin

Muscle aches are the usual reason people stop a statin. A 2022 Lancet analysis of 19 large blinded statin trials by the Cholesterol Treatment Trialists' Collaboration found that most of those aches also happen on placebo 12.

In blinded trials only about 1 in 15 first-year muscle complaints on a statin were caused by the drug.

LifeFrom, Atorvastatin, from the CTT analysis 12

Prescribers commonly try a short break, a different statin, a lower dose or an every-other-day schedule before calling a person statin-intolerant, and check creatine kinase and thyroid function if muscles hurt, since an underactive thyroid causes aches of its own (a TSH test checks it). If a statin still will not work, the non-statins above can stand in, alone or together. Red yeast rice contains monacolin K, the same compound as the statin lovastatin, in amounts that vary between products, and berberine lowers LDL a little; neither has outcome trials, so neither stands in for a prescribed drug.

The blood tests that show a medicine is working

A lipid panel 4 to 12 weeks after starting or changing a cholesterol medicine shows your own response, then every 3 to 12 months once LDL is steady 1. Read LDL against your goal and non-HDL cholesterol (total cholesterol minus HDL) as the second check. The 2026 guideline suggests apoB, a count of LDL-type particles, may be measured in selected people, such as those with diabetes, high triglycerides or risk left over once LDL is at goal; it also recommends measuring Lp(a) at least once in every adult 1. Safety tests depend on the drug: ALT at the start, CK only for muscle symptoms, uric acid on bempedoic acid, and HbA1c (average blood sugar) if blood sugar was already near the type 2 diabetes range before a statin.

An ALT more than 3 times the upper limit of normal, a raised CK with muscle pain, or uric acid climbing toward the gout range goes to the prescriber promptly; do not stop or change the medicine on your own while you wait. Muscle pain with dark urine needs same-day care.

You can work out non-HDL from any panel, or let the cholesterol ratio calculator do it. When LDL and apoB tell different stories, apoB vs LDL explains which to trust, and how to read your lipid panel walks through every line.

Interactive

Your non-HDL cholesterol

The closest stand-in for apoB you can get from a standard panel. Nothing leaves your browser.

Enter your total and HDL cholesterol to see your non-HDL.
Have your own numbers?Have your results? Read them free.Drop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.Read my results

What to ask at your next appointment

  1. Which risk group am I in, and what LDL goal are we aiming for?
  2. If I am not at goal on my current statin dose, would adding ezetimibe or another drug get me there?
  3. When should I repeat my lipid panel, and which safety tests do I need on this drug?
  4. Should I have Lp(a) and apoB measured?
Free, no accountRead your blood testHolding lipid panels from before and after a new cholesterol medicine? Read every line of both, free.Read my results
Citations
  1. Blumenthal RS, Morris PB et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology, 2026;87(19):2624-2757
  2. Silverman MG et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 2016;316(12):1289-1297
  3. Cannon CP et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). New England Journal of Medicine, 2015;372:2387-2397
  4. Nissen SE et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). New England Journal of Medicine, 2023;388:1353-1364
  5. Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). New England Journal of Medicine, 2017;376:1713-1722
  6. Schwartz GG et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). New England Journal of Medicine, 2018;379:2097-2107
  7. Bohula EA et al. Evolocumab in patients without a previous myocardial infarction or stroke (VESALIUS-CV). New England Journal of Medicine, 2025
  8. Ray KK et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). New England Journal of Medicine, 2020;382:1507-1519
  9. US Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol, July 2026
  10. Giugliano RP et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet, 2017;390:1962-1971
  11. O'Donoghue ML et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation, 2019;139:1483-1492
  12. Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet, 2022;400:832-845
  13. Kim BK et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING). Lancet, 2022;400:380-390
  14. Klug EQ, Llerena S et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial (LIBerate-HR). JAMA Cardiology, 2024;9(9):800-807
  15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA, 1984;251(3):351-364

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.